Philipp Schreppel
Senior Director Business Development Ethris GmbH
Philipp Schreppel is Executive Director of Business Development at Ethris, where he leads business development activities focused on out-licensing the company’s therapeutic programmes and mRNA technology platform, fundraising and investor relations. He brings experience in life sciences strategy, having previously advised private equity investors on commercial due diligence and value creation across the healthcare and pharmaceutical sectors.
Philipp holds a PhD in Medicinal Chemistry and a degree in Pharmacy from the University of Vienna, alongside a BSc in Business Administration from the Vienna University of Economics and Business. At Ethris, he supports the advancement and commercialisation of innovative mRNA therapeutics, including programmes targeting respiratory diseases and mucosal vaccine development.
Seminars
- Exploring localised respiratory delivery of therapeutic mRNA to achieve dose-dependent protein expression while minimising systemic exposure
- Evaluating the safety, tolerability and biodistribution of nasal and inhaled mRNA formulations to support therapeutic development in respiratory diseases
- Sharing Phase IIa clinical proof-of-concept findings from a rhinovirus challenge study in asthma patients, assessing therapeutic activity and symptom reduction
- Addressing investor expectations: balancing early-stage innovation with clinical validation requirements
- Understanding how political & regulatory headwinds impact RNA therapeutic investment (vaccine hesitancy, government funding changes)
- Navigating the tension between long-term scientific development & short-term investor exit timelines
